Hypothalamic Obesity Market: Epidemiology, Pipeline Therapies, and Leading Companies | DelveInsight | Rhythm Pharmaceuticals and Others

The hypothalamic obesity market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM hypothalamic obesity market size from 2020 to 2034. The report also covers current hypothalamic obesity treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Emerging therapies for Hypothalamic Obesity, including LB54640 and others, are anticipated to drive significant growth in the Hypothalamic Obesity market in the coming years.

DelveInsight has launched a new report on "Hypothalamic Obesity - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Hypothalamic Obesity, historical and forecasted epidemiology as well as the Hypothalamic Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for a detailed sample report @ https://www.delveinsight.com/report-store/hypothalamic-obesity-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Hypothalamic Obesity Market Report:

*
Hypothalamic obesity is a complex disorder typically caused by damage to the hypothalamus due to brain tumors, surgery, radiation, head trauma, or genetic abnormalities. Studies estimate that the annual incidence of tumor- or treatment-related hypothalamic obesity (TTR-HO) in Germany ranges from 0.7 to 1.7 cases per million people.

*
Common symptoms include excessive hunger, an inability to feel full, rapid weight gain, daytime sleepiness, disrupted circadian rhythms, and dysregulation of thirst, body temperature, heart rate, and blood pressure.

*
Conventional treatment strategies focus on calorie-restricted diets, exercise, and pharmacotherapy, though no fully effective treatment exists. Pharmacological approaches target alterations in efferent pathways, often using off-label therapies such as sympathomimetic appetite suppressants, leptin-sensitizing agents, hormone replacement therapy, stimulants, and GLP-1 agonists.

*
Recent advances offer promising developments. In January 2024, Rhythm Pharmaceuticals completed patient screening for a pivotal Phase III trial evaluating setmelanotide in individuals with acquired hypothalamic obesity. Enrollment exceeded expectations, with over 140 patients actively screened and undergoing baseline assessments.

*
In the same month, Rhythm Pharmaceuticals also entered a global licensing agreement with LG Chem for LB54640, an investigational oral MC4R agonist in Phase II trials, reflecting increasing pharmaceutical efforts to address hypothalamic obesity.

*
Despite these advances, there remains a critical need for further clinical research to manage the growing prevalence of hypothalamic obesity effectively.

*
Key companies such as Rhythm Pharmaceuticals and others are actively developing new therapies to improve the treatment landscape. Promising pipeline candidates in various stages include LB54640, IMCIVREE, and others.

*
In March 2025, Rhythm Pharmaceuticals announced that the U.S. FDA awarded Breakthrough Therapy Designation to setmelanotide for the treatment of hypothalamic obesity. This designation is designed to accelerate the development and review of therapies that show significant improvements over existing treatments for serious or life-threatening conditions.

*
During the same month, Japan's Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation to setmelanotide for acquired hypothalamic obesity, supporting the drug's development and regulatory approval for this rare condition.

Key benefits of the Hypothalamic Obesity market report:

*
Hypothalamic Obesity market report covers a descriptive overview and comprehensive insight of the Hypothalamic Obesity Epidemiology and Hypothalamic Obesity market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

*
The Hypothalamic Obesity market report provides insights on the current and emerging therapies.

*
Hypothalamic Obesity market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Hypothalamic Obesity market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hypothalamic Obesity market.

Got queries? Click here to know more about the Hypothalamic Obesity Market Landscape [https://www.delveinsight.com/sample-request/hypothalamic-obesity-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Hypothalamic Obesity Overview

Hypothalamic obesity is a rare condition caused by damage to the hypothalamus, the brain region that regulates hunger and metabolism. Such damage can result from tumors (e.g., craniopharyngiomas), brain injuries, or surgical interventions, disrupting appetite control and energy balance. This leads to uncontrolled weight gain, reduced energy expenditure, and a poor response to conventional weight-loss methods.

To know more about hypothalamic obesity, treatment options, visit: https://www.delveinsight.com/report-store/hypothalamic-obesity-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Hypothalamic Obesity Market Outlook

Leading companies such as LG Chem and Rhythm Pharmaceuticals are progressing their drug candidates through various stages of clinical development to investigate potential treatments for hypothalamic obesity.

This analysis offers a detailed overview of the hypothalamic obesity market, examining both approved therapies and late-stage pipeline candidates. It assesses their impact considering factors such as annual treatment costs, inclusion/exclusion criteria, mechanisms of action, patient adherence, market demand, growing patient populations, target demographics, expected launch timelines, competition with existing treatments, brand positioning, market influence, and insights from key opinion leaders.

Discover how the hypothalamic obesity market is rising in the upcoming years, click: https://www.delveinsight.com/sample-request/hypothalamic-obesity-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Hypothalamic Obesity Emerging Drugs

*
IMCIVREE (setmelanotide): Rhythm Pharmaceuticals

*
LB54640 (LR19021): LG Chem/ Rhythm Pharmaceuticals

Scope of the Hypothalamic Obesity Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hypothalamic Obesity Companies: Rhythm Pharmaceuticals, and others

*
Key Hypothalamic Obesity Therapies: IMCIVREE, LB54640, and others

*
Hypothalamic Obesity Therapeutic Assessment: Hypothalamic Obesity current marketed and Hypothalamic Obesity emerging therapies

*
Hypothalamic Obesity Market Dynamics: Hypothalamic Obesity market drivers and Hypothalamic Obesity market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hypothalamic Obesity Unmet Needs, KOL's views, Analyst's views, Hypothalamic Obesity Market Access and Reimbursement

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Hypothalamic Obesity Patient Share (%) Overview at a Glance

5. Hypothalamic Obesity Market Overview at a Glance

6. Hypothalamic Obesity Disease Background and Overview

7. Hypothalamic Obesity Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypothalamic Obesity

9. Hypothalamic Obesity Current Treatment and Medical Practices

10. Unmet Needs

11. Hypothalamic Obesity Emerging Therapies

12. Hypothalamic Obesity Market Outlook

13. Country-Wise Hypothalamic Obesity Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Hypothalamic Obesity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Hypothalamic Obesity Market Outlook 2034 [https://www.delveinsight.com/report-store/hypothalamic-obesity-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Hypothalamic Obesity Pipeline Insights, DelveInsight

"Hypothalamic Obesity Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hypothalamic Obesity market. A detailed picture of the Hypothalamic Obesity pipeline landscape is provided, which includes the disease overview and Hypothalamic Obesity treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypothalamic-obesity-market-epidemiology-pipeline-therapies-and-leading-companies-delveinsight-rhythm-pharmaceuticals-and-others]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.